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aBsTRacT
INTRODUCTION: Post-operative agitation (PA) is a common 
problem (20-70%) in children anaesthetised with sevoflur-
ane. Clonidine is widely used off-label in children for several 
indications, including PA; but the current level of evidence 
is limited. Our aim is to investigate the impact of prophylac-
tic intravenous (IV) clonidine administered at the end of 
surgery on the incidence and degree of PA. Furthermore, 
the pharmacokinetic profile of IV clonidine in children is not 
well established and our aim is to obtain pharmacokinetic 
data relating hereto. 
METHODS: This is a multicentre, randomised and blinded 
clinical trial in which we will be enrolling 380 children aged 
1-5 years who are planned for anaesthesia with sevoflurane 
and fentanyl. Inclusion is based on computer-generated 
randomisation (1:1) and stratified by age and site. The study 
drug is administered IV approximately 20 min. before the 
expected completion of surgery (intervention: clonidine 3 
µg per kg; placebo: equal quantity of saline). 
CONCLUSION: The primary outcome is PA measured on the 
Watcha scale. The secondary outcomes include post-opera-
tive pain relief and adverse effects, including a 30-day fol-
low-up. In total, 40 children will be allocated to drug assay 
sampling, enabling a compartmental pharmacokinetic ana-
lysis. 
FUNDING: Funded by the participating departments and by 
two unrestricted scientific grants from the Danish Society of 
Anaesthesia and Intensive. 
TRIAL REGISTRATION: This study was approved by the Dan-
ish Health and Medicines Authority (EudraCT number 2014-
001466-10), the Ethics Committee of the Capital Region of 
Denmark (H-2-2014-072) and registered with Clinicaltrials.
gov (NCT02361476).
The use of sevoflurane, a volatile anaesthetic, in paedi-
atric anaesthesia is frequent since it is unnecessary to 
establish an intravenous (IV) access prior to initiation of 
anaesthesia. This is a clear benefit for children as a nee-
dle procedure can be painful and traumatising. Various 
pharmacological interventions have been investigated 
for the intervention against post-operative agitation 
(PA) in children anesthetised with sevoflurane, including 
clonidine. Clonidine is used off-label for a number of in-
dications in children, including treatment of shivering, 
pain management and prevention of withdrawal symp-
toms following too long-term sedation, and PA.
In 2002, the use of clonidine, an alpha-2 receptor 
agonist, was proposed as a potential prophylactic inter-
vention against sevoflurane-induced PA in children [1]. 
Several trials have since been published, examining the 
role of different strategies for clonidine administration 
and dosing in the perioperative setting (Table 1). 
Presently, paediatric trials have found few safety issues, 
no serious adverse effects or significant decrease in 
blood pressure or heart rate (Table 1 and Table 2) 
However, current knowledge about pharmacokinetics of 
clonidine and the relationship between plasma concen-
trations, safety and effect on PA and pain in children re-
mains limited [2-4]. 
In a recent systematic review, alpha-2 agonists ad-
ministered during anaesthesia without premedication 
were found to reduce the incidence of PA (odds ratio = 
0.28; 95% confidence interval: 0.19-0.40, p < 0.001) [5]. 
However, only two trials with clonidine were included. 
One included 75 children, a third of whom received 1.5 
μg/kg IV clonidine after induction, and this did not signif-
icantly reduce the incidence of PA [6]. The other includ-
ed 120 children received either clonidine 2 μg/kg or pla-
cebo after induction, and the incidence of PA in these 
children decreased significantly from 41% to 22% [7]. 
The previously published trials have suffered from 
various methodological shortcomings such as small sam-
ple sizes, high risk of bias, low doses and various routes 
of administration (Table 1 and Table 2) [8]. Furthermore, 
previous trials have suggested that clonidine in lower 
dosages of 1 μg/kg may reduce the incidence of PA by as 
much as 50%. This reduction is presumed to be dose- 
dependent; and as a consequence there is an urgent 
need for studies examining the impact of higher doses. 
De spite the known analgesic properties of clonidine, an 
optimal dose in a perioperative setting remains to be es-
tablished as suggested in a recently published Cochrane 
review [9]. Equally important, the role of clonidine for 
other relevant outcomes such as shivering and post- 
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operative nausea and vomiting (PONV) remains to be es-
tablished. These outcomes are not only patient-relevant 
but may have important cost-benefit advantages such as 
reduced time to discharge from the recovery ward and 
reduced length of stay in hospital.
The purpose of this trial is to investigate whether  
IV clonidine 3 μg/kg, administered approximately 20 
min. before the expected completion of surgery, will  
reduce the incidence of PA and pain in children anaes-
thetised with sevoflurane. Safety issues and serious ad-
verse events are evaluated for a follow-up period of 30 
days. Additionally, in a representative group of the chil-
dren, pharmacokinetic (PK) data will be obtained for 
characterisation of the PK profile and correlation of 
 plasma concentrations of clonidine to the clinical re-
sponse.
TaBlE 1
Overview of paediatric clonidine-trials for prevention of post-operative agitation. 
Reference number and design intervention Results safety Risk of bias
Ghai et al, 2010 n = 120  
RCT  
Premedication:  
midazolam 0.5 mg/kg PO
IV: placebo (n = 40),  
clonidine 1 µg/kg (n = 39),  
2 µg/kg (n = 41) 
Agitation: 27,5%, 5,1%, 0% No significant impact on 
blood pressure or pulse rate
Unclear
Tesoro et al, 2005 n = 169 RCT, blinded  
Premedication:  
midazolam 0.5 mg/kg  
PO and nerve block or  
local infiltration
IV, just before start of  
surgery: clonidine 2 µg/kg  
(n = 91), placebo (n = 78) 
Incidence of agitation  
was reduced by 57% (p = 0.029)  
Incidence of severe agitation was 
reduced by 67% (p = 0.064)
No respiratory adverse 
effects  
Pulse rate: 116 ± 32,  
112 ± 28 per min.  
MAP: 92 ± 18, 87 ± 21 mmHg
High 
Tazeroualti et al,  
2007
n = 60 RCT, blinded  
Paracetamol and  
penile block
PO, 30 min. prior to anaesthesia:  
midazolam 0.5 mg/kg  
(n = 20); clonidine 2 µg/kg (n = 20),  
4 µg/kg (n = 20) 
Agitation in the 1st post-operative 
h: 60%, 40%, 25% (p = 0.025)
No difference between 
groups regarding haemo-
dynamic parameters
High 
Ghosh et al, 2011 n = 90 RCT, blinded Clonidine added to epidural:  
1 µg/kg, 0.75 µg/kg, 0 µg/kg
Agitation: 6,6%, (p < 0.05),  
26.6%, 40%
No effect on haemodynamic 
or respiratory systems 
High 
Bock et al, 2002 n = 80 RCT, blinded  
Premedication:  
midazolam 0.4 mg/kg PO
Clonidine added to epidural:  
1 µg/kg (n = 18), 3 µg/kg (n = 18),  
0 µg/kg (n = 18), 3 µg/kg IV (n = 18)
Agitation: 20%, 0%, 39%, 5% No relevant respiratory or 
haemodynamic adverse 
events, despite a significant 
lower blood pressure in the  
3 µg/kg group
Unclear
Kulka et al, 2001 n = 40 RCT, blinded  
Penile block  
Premedication:  
midazolam 0.5 mg/kg PO
IV, after induction:  
clonidine 2 µg/kg, placebo 
Number of patients  
With agitation: 2 vs 16 (p < 0.001) 
Severe agitation: 0 vs 6 (p < 0.05)
No intraoperative difference 
between groups regarding 
haemodynamics 
Despite a significant lower 
blood pressure post-opera-
tively in the clonidine group, 
no episodes of bradycardia or 
hypotension was recorded
High
Almenrader et al,  
2007
n = 64 RCT, open  
Ibuprofen  
Paracetamol
Premedication PO:  
midazolam 0.5 mg/kg (n = 30),  
clonidine 4 µg/kg (n = 30)
Agitation: 7% ,  
0% (p = 0.13)
- High 
Bergendahl et al,  
2004
n = 100 RCT, blinded  
Paracetamol
Premedication rectal:  
midazolam 0.3 mg/kg (n = 52),  
clonidine 5 µg/kg (n = 48)
Lower pain score (p = 0.011)  
Higher sedation score  (p ≤ 0.001) 
Lower confusion (p = 0.001)
- High
IV = intravenously; MAP = mean arterial pressure; PO = orally; RCT = randomised clinical trial.
TaBlE 2
Previous trials with intravenous clonidine administered after induction of anaesthesia to prevent post-operative agitation, without premedication and local anaesthesia.
Reference number and design intervention Results safety Risk of bias
Lankinen et al,  
2006 [6]
n = 75
RCT, blinded
Tropisetron 0.1 mg/kg (n = 25)
Clonidine 1.5 µg/kg (n = 24)
Placebo (n = 26)
Agitation: tropisetron 32%, 
 clonidine 54%, placebo 62%
No adverse events Unclear
Malviya et al,  
2006 [7]
n = 120
RCT, blinded
Clonidine 2 µg/kg (n = 59)
Placebo (n = 61)
Moderate-severe agitation:  
placebo 41%, clonidine 22%  
(p < 0.03)
No adverse events High
RCT = randomised clinical trial. 
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mEThOds
We have adhered to the CONSORT statement and SPIRIT 
guideline, and the trial was approved by the National 
Committee on Biomedical Research Ethics (H-2-2014-
072), the Danish Medicines Agency (EudraCT 2014-
001466-10) and the Danish Data Protection Agency (30-
1348). The trial was registered with clincialtrials.gov 
(NCT02361476). We will adhere to the harmonised tri-
partite guidelines for good clinical practice (ICH GCP), in-
cluding the Helsinki Declaration, and our trial will be 
monitored by independent monitors from the GCP unit 
at Rigshospitalet.
Prior to protocol writing, we systematically  
sear ched PubMed, EMBASE and the Cochrane Library for 
relevant references in order to define the ideal dose and 
study design using keywords such as: PA, sevoflurane, 
children, preclinical studies and clonidine. We applied 
no language or time restrictions.
The PREVENT AGITATION trial is designed as a ran-
domised, placebo-controlled, blinded, multicentre su-
per iority trial with two parallel groups. The trial will be 
conducted at Rigshospitalet: Department of Anaesthe-
siology, The Juliane Marie Centre, a tertiary hospital 
with approximately 4,000 children admitted for elective 
surgery a year; and the Departments of Anaesthesiology 
at Vejle Hospital and Zealand University Hospital, Køge. 
These are urban district hospitals with an annual census 
of 700 and 600 children, respectively. Participant inclu-
sion and exclusion criteria are given in Table 3.
Centralised randomisation is performed on a web-
site produced by the Copenhagen Trial Unit, Rigshos-
pitalet, using adequate computer random number 
generation to establish the allocation sequence. 
Randomisation will be performed as block randomisa-
tion with a 1:1 allocation stratified for site and age (< 2 
or ≥ 2 years) aiming to limit baseline imbalance for these 
variables. Participants, investigators, other healthcare 
providers, statisticians and authors of the trial report 
will be blinded to the assignment. Trial medications are 
delivered by The Hospital Pharmacy of the Capital 
Denmark Region in identical containers, relabelled with 
printed randomisation numbers.
Intervention group: 3 μg/kg of IV clonidine (Cata-
presan, Boehringer Ingelheim, 150 μg/ml, 1 ml vials).
Control group: equal quantity of IV saline (sodium 
chloride, Skanderborg Pharmacy, 9 mg/ml, 1 ml vials).
The trial results will remain blinded to the authors 
during preparation of the manuscript. Thus, two manu-
scripts will be prepared in which conclusions are based 
either on the assumption that the first group is the inter-
vention group, while the other group is the control 
group and vice versa [10]. Once the manuscripts are ap-
proved by the Steering Committee, the results will be 
unveiled and the correct manuscript will be published.
Primary outcome
The primary outcome is the incidence of agitation meas-
ured by the Watcha Scale, which is validated in children 
in a post-operative setting. Scores 3-4 will be considered 
agitated [11-13].
secondary outcomes
– Opioid requirements in the recovery room.
– Time to first administration of opioid in the 
recovery room.
– Pain score, assessment with the “face, leg, activity, 
cry, consolability” scale (only part B).
– Adverse events.
Exploratory outcomes
– Time to discharge from the recovery room.
– Incidence of shivering.
– Incidence of PONV.
Part a
Information is provided to all parents of children fulfill-
ing the inclusion criteria prior to arrival at one of the 
three participating hospitals. Written informed consent 
is obtained from both parents. Data will be collected on 
paper case record forms (CRF). Any protocol violation 
will be recorded in the CRF. All relevant information will 
be recorded in the patient chart and CRF, including as-
sessment of eligibility for inclusion, randomisation num-
ber, age, weight, type of surgery, administration of any 
type of analgesics or sedatives prior to arrival at the op-
TaBlE 3
Inclusion and exclusion criteria. 
We will include children
1-6 yrs of age
Scheduled for surgery with sevoflurane anaesthesia 
We will exclude children with any of the following
ASA classification > 2
Premedication with clonidine
Ex-premature: born before week 37 + 0 and < 60 weeks old 
Intubated before anaesthesia and/or no plans for extubation after  
anaesthesia 
Critical illness with haemodynamic instability 
Active bleeding 
Cancer 
Cardiac diseases including arrhythmias
Malignant hyperthermia 
Mental retardation 
Neurological illness with agitation-like symptoms 
Weight > 50 kg
Allergy to clonidine 
Patients treated with methylphenidate
ASA = American Society of Anesthesiologists.
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erating theatre, and when possible measurement of 
blood pressure, heart rate and oxygen saturation prior 
to the induction of anaesthesia, together with baseline 
agitation score.
Anaesthesia will be induced either via a mask with 
sevoflurane and 100% oxygen or IV propofol. Airway 
management and volume resuscitation will be according 
to local and national guidelines. No other opioids or hyp-
notics than fentanyl, sevoflurane and propofol (for in-
duction only) are allowed during surgery. When muscu-
lar relaxation is needed, primarily rocuronium bromide 
or suxametonium is to be used. The anaesthesia is main-
tained solely with sevoflurane and fentanyl as analgesic 
with no limitation on dosage (clinical assessment of 
need). Paracetamol will be administered after induction 
according to weight and age if no contradiction and if  
it was not already administered prior to arrival in the  
operating theatre. Local, peripheral and central nerve 
blocks are permitted, but without adding e.g. clonidine. 
All administered drugs and dosages and their time of  
administration will be recorded throughout the trial  
period. Blood pressure, pulse and oxygen saturation are 
to be registered every 5 min. after induction of anaes-
thesia and every 15 min. in the recovery room.
In consultation with the surgeon and approximately 
20 min. prior to awakening, the trial drug will be admin-
istered IV. This is based on the rationale of achieving 
maximum possible benefit of clonidine approximately 15 
min. after administration. After awakening, we will regis-
ter the agitation score every 15 min. until discharge.  
In the post-operative recovery unit, only fentanyl and 
morphine are allowed to alleviate pain, and propofol is 
allowed to treat agitation according to a flow chart 
(Figure 1).
After discharge, patients will be followed up at 24 
hours for any adverse events and at 30 days to register 
serious adverse events.
Part B – pharmacokinetics
In part B of the study, all patients are treated as de-
scribed in Part A. Additionally, blood samples will be col-
lected for pharmacokinetic analysis after administration 
of the study drug. Due to the possible differences in the 
distribution and elimination of clonidine in children 
younger than two years, we will carry out separate ana-
lyses for children older than two years and for children 
between one and two years. Blood samples are taken 
through a peripheral intravenous catheter at baseline 
(before study drug administration) and at 5, 10, 15, 30, 
60 min. post dose and additionally for every hour until 
discharge from the recovery room. For each blood sam-
ple, 2 ml of heparinised blood is collected for analysis of 
the plasma clonidine concentration. The maximum num-
ber of blood samples drawn from each patient is nine. 
Blood samples are centrifuged immediately after collec-
tion, and the plasma samples are stored at –80 °C pend-
ing analysis.
statistics
Using a 25% PA incidence from previously published 
studies and systematic reviews [14], a total of 380 chil-
dren (190 per group) were calculated with the software 
”Power and Sample Size” to provide a 80% power tar-
geting a relative risk reduction (RRR) of 41%, with a max-
imal 5% risk of type 1 error.
The proposed incidence of PA closely resembles the 
findings of an internal audit (conducted with the blind-
ing conserved) at the three study sites after trial com-
mencement. We consider the proposed RRR as a realis-
tic target and clearly more realistic than 50%, which is 
often perceived in the literature as a realistic beneficial 
effect. As a consequence, our sample size was increased 
from 304 to 380 by addressing a RRR of 41% instead of 
50%.
We will assess and report all outcomes as “inten-
tion-to-treat” analysis including all randomised children 
meeting the inclusion criteria and not fulfilling the exclu-
sion criteria with a standing consent to participate.
The primary analyses will be differences in out-
comes adjusted for stratification variables. The second-
ary analyses will be analyses adjusted for baseline vari-
ables using multiple logistic regression in accordance 
with ICH-GCP recommendations on statistical principles 
FigURE 1
Flow chart for assessment and treatment of agitation and pain in the recovery room. Intervention if 
Watcha-score is 3 or 4. If pain is the most probable cause (e.g. because of failing local anaesthesia), the 
patient is treated for pain. If pain is not the most probable cause or the clinician is in doubt, the patient 
is treated for agitation.
Agitation score is to be measured every 15 min. Blood pressure,  
pulse and saturation, if possible at the same time
Asses if the score most likely is due to pain or not
Most likely due to pain
1: Fentanyl 1-2 μg/kg IV
2: Morphine 25 μg/kg IV
Probably not due to pain = agitation
Crying, inconsolable           3
Severely agitated           4
Crying, consolable           2
Calm or asleep           1
1: Propofol 0,5-1 mg/kg IV
And/or
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for clinical trials (E9). Complete case analysis will be  
carried out if the overall level of missing data is less than 
5%. However, if exceeding the limit of 5% missing data 
and if Littles’ test is statistically significant, multiple im-
putation will be used and considered the primary result 
of the trial to reduce bias from complete case analysis 
[15-17]. We will present “worst-case” and “best-case” 
scenarios. p < 0.05 will be considered statistically signifi-
cant.
For each group, all children will be analysed for the 
primary outcome. For each primary and secondary out-
come, the results and estimated effect sizes with 95% 
confidence interval will be provided. For binary out-
comes, we will provide both absolute and relative effect 
sizes. Time-to-event outcomes (time to fentanyl admin-
istration and discharge) will be presented as survival 
curves using Kaplan Meier estimators, and differences 
between groups will be analysed using Cox regression 
analysis adjusted for stratification and baseline vari-
ables. We will provide detailed data for all other explor-
atory analyses (secondary and exploratory outcomes).
Subgroup analyses will be used (site, age, sex, the 
use of propofol or not, length of the operation, the  
use of premedication, preoperative Watcha score and 
the use of local, peripheral and central nerve blocks)  
[18, 19].
We will exclude patients with major protocol viola-
tions defined as failure to receive the total drug dose  
or failure to complete follow-up in a supplemental per-
protocol analysis. We will carry out statistical analyses 
before revealing the code of allocation.
Trial registration: Approved by the Danish Health and 
Medicines Authority (EudraCT number 2014-001466-10), 
the Ethics Committee of the Capital Region of Denmark 
(H-2-2014-072) and registered with Clinicaltrials.gov 
(NCT02361476).
discUssiOn
The results of a newly published trial in a vulnerable 
group of adults have prompted a more detailed assess-
ment of paediatric data regarding harm and indication 
for use [20]. We do, however, not expect any problems 
or harm in this trial. First of all because of the different 
pharmacodynamics and pharmacokinetics in children. 
Secondly, because this trial has fundamental differences 
in patient population, dose, timing and duration of the 
intervention. And, finally, because, hypotension and 
bradycardia which are well-known side effects in adults 
have not been reported at similar rates in children in any 
of the published systematic reviews of trials.
PA due to volatile anaesthetic agents is more fre-
quently observed in small children than in older children 
and adults. This remains a great challenge for healthcare 
providers and causes great discomfort for children and 
their parents. Since volatile anaesthetic agents are used 
extensively in children, PA constitutes a great problem 
which we hope to alleviate and significantly reduce by 
carrying out this multicentre, randomised clinical trial 
with low risk of bias in accordance with the CONSORT 
statement and the SPIRIT initiative. 
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